Abstract
The genomics and proteomics sciences have fundamentally changed the ways in which drug targets are being identified, characterized and validated. Here we review how genomics and proteomics research is improving our understanding of genetic determinants of drug susceptibility and response and, conversely, how organic small molecules mediate their pharmacological effects by modulating genome and proteome activities. We also examine the effect this improved understanding has on the drug discovery and development process.
Keywords: Genomics, proteomics, pharmacogenetics, pharmacogenomics, chemical proteomics, drug resistance, activitybased protein profiling, yeast three-hybrid
Current Drug Targets
Title: Investigating the Molecular Basis of Drug Action and Response: Chemocentric Genomics and Proteomics
Volume: 7 Issue: 4
Author(s): Gabriele Zybarth and Nikolai Kley
Affiliation:
Keywords: Genomics, proteomics, pharmacogenetics, pharmacogenomics, chemical proteomics, drug resistance, activitybased protein profiling, yeast three-hybrid
Abstract: The genomics and proteomics sciences have fundamentally changed the ways in which drug targets are being identified, characterized and validated. Here we review how genomics and proteomics research is improving our understanding of genetic determinants of drug susceptibility and response and, conversely, how organic small molecules mediate their pharmacological effects by modulating genome and proteome activities. We also examine the effect this improved understanding has on the drug discovery and development process.
Export Options
About this article
Cite this article as:
Zybarth Gabriele and Kley Nikolai, Investigating the Molecular Basis of Drug Action and Response: Chemocentric Genomics and Proteomics, Current Drug Targets 2006; 7 (4) . https://dx.doi.org/10.2174/138945006776359430
DOI https://dx.doi.org/10.2174/138945006776359430 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design Gabapentin and Pregabalin for the Acute Post-operative Pain Management. A Systematic-narrative Review of the Recent Clinical Evidences
Current Drug Targets Renaissance of the Biologically Active Vitamin A Derivatives: Established and Novel Directed Therapies for Cancer and Chemoprevention
Current Pharmaceutical Design CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets Nanoparticle-based Drug Delivery Systems for Solid Brain Tumors
Current Nanoscience Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design Study of Parasitic Infections, Cancer, and other Diseases with Mass-Spectrometry and Quantitative Proteome-Disease Relationships
Current Proteomics Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis: Consensus Statements for the United Arab Emirates
New Emirates Medical Journal Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer
Current Signal Transduction Therapy Extra-Hepatic Isozymes from the CYP1 and CYP2 Families as Potential Chemotherapeutic Targets
Current Topics in Medicinal Chemistry 2D QSAR Studies on a Series of Quinazoline Derivatives as Tyrosine Kinase (EGFR) Inhibitor: An Approach to Design Anticancer Agents
Letters in Drug Design & Discovery Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Editorial: “Strategies and Methods to Prevent Fluoropyrimidine-associated Toxicities”
Clinical Cancer Drugs Lymnaea EGF and Gigantoxin I, Novel Invertebrate Members of the Epidermal Growth Factor Family
Current Pharmaceutical Design